Spectrum and Impact of Reported Side Effects of Omalizumab in Patients With Chronic Urticaria: A Long‐Term Multicentre Real‐World Study
Clinical & Experimental Allergy2025Vol. 55(6), pp. 481–492
Citations Over TimeTop 10% of 2025 papers
Reineke Soegiharto, Esther Van der Wind, Mehran Alizadeh Aghdam, Jennifer Astrup Sørensen, Esmee van Lindonk, Fatih Demir, Nasser Mohammad Porras, Yoshimi Matsuo, Lea Kiefer, André C. Knulst, Marcus Maurer, Carla Ritchie, Michael Rudenko, Emek Kocatürk, Roberta Fachini Jardim Criado, Stamatios Gregoriou, Tatjana Bobylev, Andreas Kleinheinz, Shunsuke Takahagi, Michihiro Hide, Ana M. Giménez‐Arnau, Andaç Salman, Rabia Öztaş Kara, Bahar Sevimli Dikicier, Martijn B. A. van Doorn, Simon Francis Thomsen, J. M. P. A. van den Reek, Heike Röckmann
Abstract
The safety and tolerability of omalizumab was confirmed. Notably, the wide variation in reported side effects across centres suggests that differences in awareness influence reporting. Hair loss was more prevalent than described before, warranting extra attention. Side effects were more often reported in patients whose characteristics suggest reduced effectiveness of omalizumab, possibly related to a negative association with omalizumab and suggesting increased disease burden. Availability of new therapies might increase the impact of side effects on treatment decisions, not only in omalizumab-refractory patients but potentially even among good responders.
Related Papers
- → Omalizumab anaphylaxis occurring outside the recommended observation times(2017)3 cited
- → OMALIZUMAB AS A THERAPEUTIC ALTERNATIVE FOR CHRONIC URTICARIA(2008)9 cited
- → The Potential Role of Omalizumab in the Treatment of Chronic Urticaria(2014)3 cited
- → Effects of omalizumab on chronic urticaria not responding to recommended therapy(2012)
- → Clinical outcomes of patients with idiopathic anaphylaxis receiving omalizumab(2021)